Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 13, 2022
Event: Regulation FD Disclosure regarding an update to the Company's Corporate Presentation intended for use at conferences and investor meetings.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the availability of an updated corporate presentation and does not contain financial statement data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The only material change noted is the update to the Corporate Presentation attached as Exhibit 99.1.
Guidance, Outlook, and Risks
Management Commentary: The Company updated its Corporate Presentation for investor relations purposes.
Legal Disclaimer: The information contained in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that Section. It shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Review the attached Corporate Presentation (Exhibit 99.1) for updated strategic information, as the 8-K text itself contains no financial data.
- Verify that the Corporate Presentation is not considered "filed" for liability purposes under Section 18 of the Exchange Act.
- Confirm the trading symbol (MTNB) and exchange (NYSE American) for the Company's common stock.